Spots Global Cancer Trial Database for Chemotherapy in Treating Patients With Advanced Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chemotherapy in Treating Patients With Advanced Kidney Cancer
Official Title: A Phase Two Study Of Fenretinide In Renal Cell Cancer
Study ID: NCT00011973
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced kidney cancer.
Detailed Description: OBJECTIVES: * Determine the response rate of patients with advanced renal cell carcinoma treated with fenretinide. * Determine progression-free and overall survival of this patient population treated with this drug. * Determine the quantitative and qualitative toxic effects of this drug in these patients. OUTLINE: Patients receive oral fenretinide twice a day for 7 days. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study within 9-21 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Ulka N. Vaishampayan, MD
Affiliation: Barbara Ann Karmanos Cancer Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
